BMC Cancer | |
Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study | |
Research Article | |
L. Laborde1  J. Thomassin-Piana2  E. Charafe-Jauffret3  J M Boher4  S. Rahal5  C. Tarpin5  J M Extra6  F. Bertucci7  R. Sabatier7  A. Gonçalves7  P. Viens7  M. Resbeut8  A. Tallet8  E. Lambaudie9  G. Houvenaeghel1,10  | |
[1] Data Management and Analysis Center, Institut Paoli-Calmettes, Marseille, France;Department of Biopathology, Institut Paoli-Calmettes, Marseille, France;Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France;Department of Biopathology, Institut Paoli-Calmettes, Marseille, France;Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France;Aix-Marseille University, Marseille, France;Department of Biostatistics, Institut Paoli-Calmettes, Marseille, France;Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd. Sainte-Marguerite, 13009, Marseille, France;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd. Sainte-Marguerite, 13009, Marseille, France;Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd. Sainte-Marguerite, 13009, Marseille, France;Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France;Aix-Marseille University, Marseille, France;Department of Radiation Oncology, Institut Paoli-Calmettes, Marseille, France;Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France;Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France;Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France;Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, U7258 CNRS, Marseille, France;Aix-Marseille University, Marseille, France; | |
关键词: Breast cancer; Adjuvant chemotherapy; Anthracycline; Taxane; Peritumoral vascular invasion; Molecular subtypes; Prognostic factors; Node-negative; | |
DOI : 10.1186/s12885-015-1746-3 | |
received in 2015-02-12, accepted in 2015-10-09, 发布年份 2015 | |
来源: Springer | |
【 摘 要 】
BackgroundAnthracycline-based adjuvant chemotherapy improves survival in patients with high-risk node-negative breast cancer (BC). In this setting, prognostic factors predicting for treatment failure might help selecting among the different available cytotoxic combinations.MethodsBetween 1998 and 2008, 757 consecutive patients with node-negative BC treated in our institution with adjuvant FEC (5FU, epirubicin, cyclophosphamide) chemotherapy were identified. Data collection included demographic, clinico-pathological characteristics and treatment information. Molecular subtypes were derived from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status and Scarff-Bloom-Richardson (SBR) grade. Disease-free survival (DFS), distant disease-free survival (DDFS) and overall survival (OS) were estimated using the Kaplan-Meier Method, and prognostic factors were examined by multivariate Cox analysis.ResultsAfter a median follow-up of 70 months, the 5-year DFS, DDFS and OS were 90.6 % (95 % confidence interval (CI): 88.2–93.1), 92.8 % (95 % CI: 90.7–95) and 95.1 % (95 % CI, 93.3–96.9), respectively. In the multivariate analysis including classical clinico-pathological parameters, only grade 3 maintained a significant and independent adverse prognostic impact. In an alternative multivariate model where ER, PR and grade were replaced by molecular subtypes, only luminal B/HER2-negative and triple-negative subtypes were associated with reduced DFS and DDFS.ConclusionsNode-negative BC patients receiving adjuvant FEC regimen have a favorable outcome. Luminal B/HER2-negative and triple-negative subtypes identify patients with a higher risk of treatment failure, which might warrant more aggressive systemic treatment.
【 授权许可】
CC BY
© Rahal et al. 2015
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202311093238013ZK.pdf | 1119KB | download |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]
- [40]
- [41]